Tumors of the Endocrine System

Norton, Jeffrey A.

doi:10.1007/0-387-31056-8_56

Cited by 5 publications

(13 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ans. Flushing: the mediators implicated are histamine, tachykinins (neuropeptide K and substance P) and prostglandins E and F. Serotonin does not cause flushing, but is known to provoke an attack [2]. Diarrhoeas: Serotonin is responsible for the diarrhoea and produces the same by its effects on gut motility, causing fat malabsorption and inducing a secretary state in the small intestine [I].…”

Section: Ql) What Was Your Clinical Diagnosis At Admission?mentioning

confidence: 99%

“…These fibrous deposits tend to cause constriction and deformity of pulmonary and tricuspid valves [3,4]. Edema: Edema is result of right heart failure and protein malnutrition due to excess utilisation oftryptophan in the diet (used for synthesis of serotonin [2].…”

Section: Ql) What Was Your Clinical Diagnosis At Admission?mentioning

confidence: 99%

“…Hence the tumors usually become symptomatic only after hepatic metastasis occur, as the mediators bypass the hepatic degradation and enter the systemic circulation. In cases of bronchial and other extraintestinal carcinoids however, whose hormone products are not cleared by liver, symptoms are produced even in absence of metastasis [1,2]. Ans.…”

Section: Q 3) Ho'w Is the Development Of Symptoms Explained In Carcinmentioning

confidence: 99%

“…Ans. Flushing occurs in 63-94% of patients with carcinoid syndrome [2,5]. Three types of flushing are seen in carcinoid syndrome.…”

Section: Q 3) Ho'w Is the Development Of Symptoms Explained In Carcinmentioning

confidence: 99%

“…systemic symptoms appear when the tumours metastatise to liver and manifest with features of carcinoid syndrome [2]. Though the symptoms and signs are characteristic of the illness, the diagnosis is often missed due to lack of awareness amongst the treating physicians.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Carcinoid Syndrome

Shankar

Kumar

Kalra

et al. 1998

Medical Journal Armed Forces India

View full text Add to dashboard Cite

Section: Ql) What Was Your Clinical Diagnosis At Admission?mentioning

confidence: 99%

Section: Ql) What Was Your Clinical Diagnosis At Admission?mentioning

confidence: 99%

Section: Q 3) Ho'w Is the Development Of Symptoms Explained In Carcinmentioning

confidence: 99%

“…Ans. Flushing occurs in 63-94% of patients with carcinoid syndrome [2,5]. Three types of flushing are seen in carcinoid syndrome.…”

Section: Q 3) Ho'w Is the Development Of Symptoms Explained In Carcinmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Carcinoid Syndrome

Shankar

Kumar

Kalra

et al. 1998

Medical Journal Armed Forces India

View full text Add to dashboard Cite

Association of Polymorphisms in ERCC2 Gene with Non-Familial Thyroid Cancer Risk

Silva¹,

Gil

Oliveira³

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

The ERCC2 protein is an evolutionary conserved ATPdependent helicase that is associated with a TFIIH transcription factor complex and plays an important role in nucleotide excision repair. Mutations in this gene are responsible for xeroderma pigmentosum and also for Cocayne syndrome and trichothiodystrophy. Several single nucleotide polymorphisms have been identified in the ERCC2 locus. Among them, a G23591A polymorphism in the codon 312 results in an Asp ! Asn substitution in a conserved region and a A35931C polymorphism in the codon 751 results in a Lys ! Gln substitution. Because these polymorphisms have been associated with an increased risk for several types of cancers, we carried out an hospital based case-control study in a Caucasian Portuguese population to evaluate the potential role of these polymorphisms on the individual susceptibility to thyroid cancer. The results obtained did not reveal a significant association between each individual polymorphism studied (G23591A and A35931C) and an increased thyroid cancer risk, but individuals homozygous for non-wild-type variants are overrepresented in patients group. The evaluation of the different haplotypes generated by these polymorphisms showed that individuals simultaneously homozygous for rare variants of both polymorphisms have an increased risk for thyroid cancer [adjusted odds ratio (OR) 3.084; 95% confidence interval (95% CI), 1.347-7.061; P = 0.008] and for papillary thyroid -type tumors (adjusted OR, 2.997; 95% CI, 1.235-7.272; P = 0.015) but not for follicular thyroid -type tumors. These results suggest that genetic polymorphisms in this gene might be associated with individual susceptibility towards thyroid cancer, mainly papillary-type tumors, but larger studies are required to confirm these results. (Cancer Epidemiol Biomarkers Prev 2005;14(10):2407 -12)

show abstract

Somatostatin Receptor Scintigraphy in Carcinoids, Gastrinomas and Cushing’s Syndrome

et al. 1994

View full text Add to dashboard Cite

High numbers of high-affinity somatostatin binding sites have been found on carcinoid tumors, gastrinomas, small cell lung cancers and the majority of medullary thyroid cancers, enabling in vivo visualization of these tumors with octreotide scintigraphy. A comparison of the results obtained at our institution and another 15 centers in Europe show a few remarkable similarities and differences. The overall sensitivity of octreotide receptor scintigraphy to detect the primary GEP tumor and its metastases is high, e.g. 80-90%. The main difference was found in gastrinomas and to a lesser extent in insulinomas. These differences might be attributed to different scanning protocols. Furthermore, octreotide scintigraphy also has a high sensitivity to localize the primary tumor and its metastases causing Cushing’s syndrome by ectopic production of ACTH or CRH. Octreotide scintigraphy is a new, sensitive and noninvasive technique to localize somatostatin receptor expressing endocrine tumors and their metastases.

show abstract

Tumors of the Endocrine System

Cited by 5 publications

References 140 publications

Carcinoid Syndrome

Carcinoid Syndrome

Association of Polymorphisms in ERCC2 Gene with Non-Familial Thyroid Cancer Risk

Somatostatin Receptor Scintigraphy in Carcinoids, Gastrinomas and Cushing’s Syndrome

Contact Info

Product

Resources

About